Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers et al. · Cancer Cell · 2005 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

IL-8 Directly Enhanced Endothelial Cell Survival, Proliferation, and Matrix Metalloproteinases Production and Regulated Angiogenesis

Aihua Li, Seema Dubey, Bhavana J. Davé et al. · The Journal of Immunology · 2003 · 1.3K citations

Medicine, Cancer Biology, Oncology +17

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

Farbod Shojaei, Xiumin Wu, Ajay K. Malik et al. · Nature Biotechnology · 2007 · 840 citations

Medicine, Cancer Biology, Oncology +13

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris et al. · Journal of Clinical Oncology · 2009 · 487 citations · Full text

Medicine, Oncology, Pharmacology +17

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

Farbod Shojaei, Xiumin Wu, Xueping Qu et al. · Proceedings of the National Academy of Sciences · 2009 · 469 citations · Full text

Medicine, Immunology, Oncology +17